Pharmaceutical

Bionomics to advance non-SSRI PTSD candidate to Phase III

Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.

Mar 22, 2024 - 00:00
Bionomics to advance non-SSRI PTSD candidate to Phase III
Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.
Read the original article

Tags:

Previous Article

Molecular glues are the latest craze in pharma research, but what are they?

Next Article

Capstan secures $175m Series B funds for CAR-T therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

Vivek Ramaswamy’s brashness made waves in the Republica...

Aug 25, 2023

Small cell lung cancer: Navigating the global clinical trial landscape

Small cell lung cancer: Navigating the global clinical ...

Dec 17, 2024

FDA clears Genentech’s Columvi for adults with R/R DLBCL

FDA clears Genentech’s Columvi for adults with R/R DLBCL

Jun 17, 2023